[
  {
    "ts": null,
    "headline": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
    "summary": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
    "url": "https://finnhub.io/api/news?id=b368b7102b2171366a74d86e916356e2323b9b11e7ede047e77905388ea1fc6e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754498100,
      "headline": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
      "id": 136251352,
      "image": "",
      "related": "TMO",
      "source": "MarketWatch",
      "summary": "Thermo Fisher Scientific Inc. stock falls Wednesday, underperforms market",
      "url": "https://finnhub.io/api/news?id=b368b7102b2171366a74d86e916356e2323b9b11e7ede047e77905388ea1fc6e"
    }
  },
  {
    "ts": null,
    "headline": "Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry",
    "summary": "Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The \"Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034\" has been added to ResearchAndMarkets.com's offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to gr",
    "url": "https://finnhub.io/api/news?id=7d4c7f45af7576785fc6d9e3e01abb610d7aee02385d1f37362b6c5ff52fa04b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754497800,
      "headline": "Cell Line Development Market Outlook Report 2025-2034: PromoCell, Novartis, Genscript Biotech, Sartorius, and Thermo Fisher Scientific Dominate the Industry",
      "id": 136239119,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Booming Biologics and Biosimilars Market Drives Global Cell Line Development Surge; CDMOs and Technological Advancements Key to Growth Cell Line Development Market Cell Line Development Market Dublin, Aug. 06, 2025 (GLOBE NEWSWIRE) -- The \"Cell Line Development Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034\" has been added to ResearchAndMarkets.com's offering. The Global Cell Line Development Market was valued at USD 7.5 billion in 2024 and is estimated to gr",
      "url": "https://finnhub.io/api/news?id=7d4c7f45af7576785fc6d9e3e01abb610d7aee02385d1f37362b6c5ff52fa04b"
    }
  },
  {
    "ts": null,
    "headline": "Thermo Fisher Q2: Pharma And Biotech Gains Offset By Weak Academic And Gov't Markets",
    "summary": "Thermo Fisher Scientific Inc.'s undervalued stock and strong Q2 results make it a Buy. Click for my updated look at TMO about growth prospects and market recovery.",
    "url": "https://finnhub.io/api/news?id=cfaccf9ce6d5ee448ad853e700ca02be09143bb28748afa54832aae9e496621e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754487067,
      "headline": "Thermo Fisher Q2: Pharma And Biotech Gains Offset By Weak Academic And Gov't Markets",
      "id": 136238824,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1873437801/image_1873437801.jpg?io=getty-c-w1536",
      "related": "TMO",
      "source": "SeekingAlpha",
      "summary": "Thermo Fisher Scientific Inc.'s undervalued stock and strong Q2 results make it a Buy. Click for my updated look at TMO about growth prospects and market recovery.",
      "url": "https://finnhub.io/api/news?id=cfaccf9ce6d5ee448ad853e700ca02be09143bb28748afa54832aae9e496621e"
    }
  },
  {
    "ts": null,
    "headline": "Bio-Techne beats quarterly estimates on strength in protein sciences unit",
    "summary": "Bio-Techne reported better-than-expected fourth-quarter revenue and profit on Wednesday, helped by steady demand for its proteins, antibodies and other products for research. The Minneapolis, Minnesota-based company develops and makes products used in medical research, drug development and diagnostics. Larger peers Thermo Fisher and Danaher last month flagged robust demand across regions for their drug development products such as instruments and analytical tools after two years of weak biotech funding.",
    "url": "https://finnhub.io/api/news?id=d9b9ffb22d280130ac28c287d3bd45c0d6eadb9459e304254a41596bd825710c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754482090,
      "headline": "Bio-Techne beats quarterly estimates on strength in protein sciences unit",
      "id": 136237313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Bio-Techne reported better-than-expected fourth-quarter revenue and profit on Wednesday, helped by steady demand for its proteins, antibodies and other products for research. The Minneapolis, Minnesota-based company develops and makes products used in medical research, drug development and diagnostics. Larger peers Thermo Fisher and Danaher last month flagged robust demand across regions for their drug development products such as instruments and analytical tools after two years of weak biotech funding.",
      "url": "https://finnhub.io/api/news?id=d9b9ffb22d280130ac28c287d3bd45c0d6eadb9459e304254a41596bd825710c"
    }
  },
  {
    "ts": null,
    "headline": "Here’s Why Kovitz Core Equity Strategy Increased Its Position in Thermo Fisher Scientific (TMO)",
    "summary": "Kovitz Investment Group Partners, LLC, an investment management company, released its “Kovitz Core Equity Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy returned 7.9% compared to the S&P 500’s 10.9% return. Equity markets saw notable volatility after the President’s “Liberation Day” tariff announcement […]",
    "url": "https://finnhub.io/api/news?id=6096ca581d06391f2787f57cfa3e5265e383e46c2e1720e35d71ef29dcc9cb64",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754482025,
      "headline": "Here’s Why Kovitz Core Equity Strategy Increased Its Position in Thermo Fisher Scientific (TMO)",
      "id": 136237315,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "TMO",
      "source": "Yahoo",
      "summary": "Kovitz Investment Group Partners, LLC, an investment management company, released its “Kovitz Core Equity Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the second quarter, the strategy returned 7.9% compared to the S&P 500’s 10.9% return. Equity markets saw notable volatility after the President’s “Liberation Day” tariff announcement […]",
      "url": "https://finnhub.io/api/news?id=6096ca581d06391f2787f57cfa3e5265e383e46c2e1720e35d71ef29dcc9cb64"
    }
  }
]